Overview
Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.Phase:
Phase 1Details
Lead Sponsor:
Novartis
Criteria
Inclusion criteria:- Male or female ≥ 50 years old, with aged related macular degeneration
- Patients with subfoveal choroidal neovascularization secondary to age-related macular
degeneration
Exclusion criteria:
- Active intraocular inflammation or ocular infection in the study eye
- Eye disease that may result in visual loss during the study
- Chronic therapy with topical, local or systemic corticosteroids.
- Pregnant or nursing (lactating) women.